Infinium Global Research Transcatheter Mitral Valve Replacement Market | Page 2

A latest report has been added to the wide database of Transcatheter Mitral Valve Replacement Market by Infinium Global Research.
This report studies the Transcatheter Mitral Valve Replacement Market by product (transapical implantation and transfemoral
implantation), region (Americas, Europe, Asia-Pacific, and Rest of the World) market status and outlook of global and major regions,
from manufacturers, and end industries. The objective of the study is to identify market sizes of different segments & countries in
recent years and to forecast the values for the next six years. Transcatheter Mitral Valve Replacement Market provides opportunities
in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape, latest trends, and product
offerings of the major companies in the Transcatheter Mitral Valve Replacement Market. According to report the global transcatheter
mitral valve replacement market is projected to grow at a CAGR of 17.9% over the forecast period of 2017-2023. The mitral valve, also
known as the bicuspid valve or left atrio-ventricular valve, is a dual-flap valve in the heart that lies between the left atrium and the left
ventricle. The mitral valve and the tricuspid valve are known collectively as the atrio-ventricular valves because they lie between the
atria and the ventricles of the heart. The mitral valve manages blood flow between left atrium and left ventricle; and prevents
backward flow of the blood into left atrium. Mitral regurgitation is leakage of blood backward through the mitral valve each time the
left ventricle contracts. This is a most common mitral valve disorder that causes abnormal blood flow. As a remedy for this problem,
surgeons use mitral surgical vale repair procedures or transcatheter replacement methods.
Market Insights
Some of the key driving factors attributing to the growth of this market include increasing number of patients with mitral valve
disorders. Approximately 7 million people in the U.S. suffer from mitral regurgitation in the U.S., and they represent almost 2% of the
nation's population. Similarly, approximately the same number of people suffers from the condition in Europe. This group includes 4.1
million people who have moderate to severe mitral regurgitation. The number of new patients suffering with mitral regurgitation
disease added each year is 250,000. Among these 4.1 million patients, only about 20% or 1.67 million are eligible for the treatment.
This creates huge opportunity for the global transcatheter mitral valve replacement market. In addition, increasing adoption of
minimally invasive procedures over traditional surgical open heart procedures, reduction in hospital stays, low risk of infection,
minimal blood loss are further propelling the market. According to world health organization (WHO), it has been estimated that the
number of people suffering from cardiovascular diseases will increase to 22.2 million by 2030. The market for TMVR is expected to
reach around USD 3.0 billion by 2022. However, there are certain restraining factors which could hamper the growth of this market,
which includes, high costs associated with the LMVD implantation compared to other therapies available for CVD diseases.